SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India - Quaterly Results

24 Jan 2023 Evaluate
The revenue zoomed 16.03% to Rs. 10323.91 millions for the quarter ended December 2022 as compared to Rs. 8897.79 millions during the corresponding quarter last year.Modest increase of 15.22% in the Net Profit was reported from. 1213.29 millions to Rs. 1397.99  millions.Operating Profit saw a handsome growth to 2376.91 millions from 1968.24 millions in the quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 10323.91 8897.79 16.03 29173.25 23255.89 25.44 32384.37 31349.82 3.30
Other Income -9.28 47.85 -119.39 73.71 164.24 -55.12 175.10 137.23 27.60
PBIDT 2376.91 1968.24 20.76 6283.14 4519.12 39.03 6621.59 8750.96 -24.33
Interest 117.56 29.56 297.70 245.56 123.52 98.80 163.52 237.74 -31.22
PBDT 2259.35 1938.68 16.54 6037.58 4395.60 37.36 6458.07 8513.22 -24.14
Depreciation 383.21 311.27 23.11 1077.88 944.79 14.09 1261.61 1184.51 6.51
PBT 1876.14 1627.41 15.28 4959.70 3450.81 43.73 5196.46 7328.71 -29.09
TAX 478.15 414.12 15.46 1224.74 878.11 39.47 1331.31 1800.87 -26.07
Deferred Tax -23.77 -7.17 231.52 -62.85 -15.20 313.49 -3.76 -169.74 -97.78
PAT 1397.99 1213.29 15.22 3734.96 2572.70 45.18 3865.15 5527.84 -30.08
Equity 242.04 248.01 -2.41 248.29 248.01 0.11 248.01 247.68 0.13
PBIDTM(%) 23.02 22.12 4.08 21.54 19.43 10.83 20.45 27.91 -26.75

Granules India Share Price

881.15 23.25 (2.71%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: